25-Feb-2026
No headlines found.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.
As of February 25, 2026, ABOS stock price climbed to $2.78 with 212,051 million shares trading.
ABOS has a beta of 1.90, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.17 to the broad based SPY ETF.
ABOS has a market cap of $168.39 million. This is considered a Micro Cap stock.
In the last 3 years, ABOS traded as high as $11.31 and as low as $.86.
The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IWC, DFAC, DFAS.
ABOS has outperformed the market in the last year with a price return of +100.0% while the SPY ETF gained +17.3%. ABOS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +63.5% and +12.6%, respectively, while the SPY returned +3.9% and +0.1%, respectively.
ABOS support price is $2.57 and resistance is $2.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.
